← Leaderboards
Joseph Kissil
Massachusetts Institute Of Technology
$14,348,310
Attributed
$15,438,190
Total exposure
17
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2008–24$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$15,831,977 · 18
By mechanism
R01$10,218,518 · 5
R21$2,248,199 · 3
R33$1,614,682 · 5
P30$808,421 · 1
R56$472,244 · 1
R61$347,117 · 1
Top collaborators
- Louis Daniel Scampavia3 shared
- Thomas D Bannister2 shared
Most similar at Massachusetts Institute Of Technology
Same institution · by research overlap
- Tyler E Jacks$53,083,831
- Milica Stojanovic$1,968,176
- Raffaele Ferrari$6,695,665
- Glenn R Flierl$3,576,516
- Patrick Heimbach$5,680,902
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoTumorMolecularSignal PathwayCellsPathway InteractionsRegulationMutationProteinsBaseMonomeric Gtp-Binding ProteinsMalignant NeoplasmsMouse ModelAnimal ModelMediatingNeurofibromin 2NeurilemmomaNeoplastic CellNeurofibromatosis 2Tumor Suppressor GenesMeningiomaTumorigenesisAllelesPharmaceutical Preparations
Grant awards (50)
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer$415,572
R01 · FY2024 · CA · contact PI
Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2$411,405
R33 · FY2024 · NS · contact PI
Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets$395,445
R01 · FY2024 · NS · contact PI
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer$428,694
R01 · FY2023 · CA · contact PI
Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2$415,703
R33 · FY2023 · NS · contact PI
Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets$411,392
R01 · FY2023 · NS · contact PI
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer$428,692
R01 · FY2022 · CA · contact PI
Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets$423,152
R01 · FY2022 · NS · contact PI
Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets$441,270
R01 · FY2021 · NS · contact PI
Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2$289,588
R61 · FY2021 · NS · contact PI
Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2$57,529
R61 · FY2021 · NS · contact PI
Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets$472,244
R56 · FY2020 · NS · contact PI
Development and validation of small molecules to treat neurofibromatosis associated schwannoma$475,000
R21 · FY2019 · NS · contact PI
Development and validation of a genetically engineered model of neurofibromatosis type 2 to facilitate discovery of neurotherapeutics$393,787
R33 · FY2019 · NS · contact PI
ConProject-002$163,131
R33 · FY2019 · NS · contact PI
ConProject-001$117,559
R33 · FY2019 · NS · contact PI
ConProject-003$113,097
R33 · FY2019 · NS · contact PI
Development and validation of small molecules to treat neurofibromatosis associated schwannoma$475,000
R21 · FY2018 · NS · contact PI
Identification and targeting of the signaling pathways underlying lung cancer.$432,000
R01 · FY2018 · CA · contact PI
Development and validation of a genetically engineered model of neurofibromatosis type 2 to facilitate discovery of neurotherapeutics$429,848
R21 · FY2018 · NS · contact PI
Development and validation of a genetically engineered model of neurofibromatosis type 2 to facilitate discovery of neurotherapeutics$477,230
R21 · FY2017 · NS · contact PI
Identification and targeting of the signaling pathways underlying lung cancer.$432,000
R01 · FY2017 · CA · contact PI
Mechanisms of cell contact inhibition and their dysregulation in cancer.$420,000
R01 · FY2017 · NS · contact PI
Identification and development of inhibitors of the Hippo-Yap pathway$351,360
R01 · FY2017 · CA · contact PI
Identification and development of inhibitors of the Hippo-Yap pathway$439,200
R01 · FY2016 · CA · contact PI
Identification and targeting of the signaling pathways underlying lung cancer.$432,000
R01 · FY2016 · CA · contact PI
Mechanisms of cell contact inhibition and their dysregulation in cancer.$420,000
R01 · FY2016 · NS · contact PI
Identification and development of inhibitors of the Hippo-Yap pathway$439,200
R01 · FY2015 · CA · contact PI
Identification and targeting of the signaling pathways underlying lung cancer.$432,000
R01 · FY2015 · CA · contact PI
Mechanisms of cell contact inhibition and their dysregulation in cancer.$413,438
R01 · FY2015 · NS · contact PI
Identification and targeting of the signaling pathways underlying lung cancer.$425,250
R01 · FY2014 · CA · contact PI
Mechanisms of cell contact inhibition and their dysregulation in cancer.$409,304
R01 · FY2014 · NS · contact PI
Mechanisms of cell contact inhibition and their dysregulation in cancer.$49,709
R01 · FY2014 · NS · contact PI
Mechanisms of cell contact inhibition and their dysregulation in cancer.$413,438
R01 · FY2013 · NS · contact PI
The Role of RAC1 in Cancer$374,614
R01 · FY2013 · CA · contact PI
Mouse Genetics Facility$146,542
P30 · FY2013 · CA · contact PI
The Role of RAC1 in Cancer$211,258
R01 · FY2012 · CA · contact PI
Mouse Genetics Facility$159,800
P30 · FY2012 · CA · contact PI
The Role of RAC1 in Cancer$148,500
R01 · FY2012 · CA · contact PI
The Role of RAC1 in Cancer$336,734
R01 · FY2011 · CA · contact PI
Mouse Genetics Facility$160,468
P30 · FY2011 · CA · contact PI
The Role of RAC1 in Cancer$347,148
R01 · FY2010 · CA · contact PI
Mouse Genetics Facility$174,879
P30 · FY2010 · CA · contact PI
The Role of RAC1 in Cancer$347,148
R01 · FY2009 · CA · contact PI
The Role of Memory T-Cells in Pathogenesis$181,939
R21 · FY2009 · CA · contact PI
Mouse Genetics Facility$166,732
P30 · FY2009 · CA · contact PI
2009 NF Conference$51,742
R13 · FY2009 · NS · contact PI
The Role of Memory T-Cells in Pathogenesis$209,182
R21 · FY2008 · CA · contact PI
The NF2 gene: elucidation of tumor suppressor function$22,906
F32 · FY2004 · CA
The NF2 gene: elucidation of tumor suppressor function$48,148
F32 · FY2003 · CA